Imidazole → 5-[3-(tert-Butyl-dimethyl-silanoxy)-propyl]-2'-trifluoromethyl-biphenyl-3,4-diamine
反応式
[NH2:1][C:2]1[C:7]([NH2:8])=[CH:6][C:5]([C:9]2[CH:14]=[CH:13][CH:12]=[CH:11][C:10]=2[C:15]([F:18])([F:17])[F:16])=[CH:4][C:3]=1[CH2:19][CH2:20][CH2:21][OH:22].N1C=CN=C1.[CH3:28][C:29]([Si:32](Cl)([CH3:34])[CH3:33])([CH3:31])[CH3:30]>C(Cl)Cl>[C:29]([Si:32]([CH3:34])([CH3:33])[O:22][CH2:21][CH2:20][CH2:19][C:3]1[C:2]([NH2:1])=[C:7]([NH2:8])[CH:6]=[C:5]([C:9]2[CH:14]=[CH:13][CH:12]=[CH:11][C:10]=2[C:15]([F:16])([F:17])[F:18])[CH:4]=1)([CH3:31])([CH3:30])[CH3:28]参加物
実験手順
3-(4,5-Diamino-2′-trifluoromethyl-biphenyl-3-yl)-propan-1-ol (101 mg, 0.324 mmol, as prepared in the previous step) was placed in an 8 mL vial equipped with a magnetic stir bar, and DCM (2 mL) was added via pipette. Imidazole (1.1 eq., 24.5 mg, 0.356 mmol) and TBSCl (1.1 eq., 53.7 mg, 0.356 mmol) were added sequentially as solids, and the reaction was stirred at RT for 2 h. The reaction was filtered, the precipitate was washed once with DCM (5 mL), and the filtrate was concentrated under reduced pressure. The crude product was purified by column chromatography on a 24-g SiO2 pre-packed column eluting with EtOAc/hexanes, 0:1 to 1:1, v/v over 30 min, yielding 93.2 mg (68%) of the title compound. 1H-NMR (400 MHz, CDCl3) δ: 7.69 (d, J=7.8 Hz, 1H), 7.49 (t, J=7.5 Hz, 1H), 7.38 (t, J=7.6 Hz, 1H), 7.32 (d, J=7.6 Hz, 1H), 6.61 (s, 1H), 6.59 (s, 1H), 3.66 (t, J=5.9 Hz, 2H), 3.52 (br. s., 4H), 2.65 (t, J=7.3 Hz, 2H), 1.75-1.87 (m, 2H), 0.91 (s, 9H), 0.07 (s, 6H).
後処理
- customvial equipped with a magnetic stir bar
- filtrationThe reaction was filtered
- washthe precipitate was washed once with DCM (5 mL)
- concentrationthe filtrate was concentrated under reduced pressure
- customThe crude product was purified by column chromatography on a 24-g SiO2 pre-packed column
- washeluting with EtOAc/hexanes, 0:1 to 1:1, v/v over 30 min
出典と根拠
- ORDレコード
- ord-06051f999f904a6694f8ed025ea663b4
- 出典データセット
- uspto-grants-2012_07
- 特許番号
- US08232409B2
反応ノート
読み込み中…